DF/HCC Immunotherapy Toxicity SPORE RFPs
DECEMBER 5, 2019
The Cancer Immunology Program of the Dana-Farber/Harvard Cancer Center (DF/HCC) and the Department of Immunology in the Blavatnik Institute at Harvard Medical School (HMS) seek translational research projects for potential inclusion in a new Specialized Program on Research Excellence (SPORE) grant that will focus on Cancer Immunotherapy Related Toxicity. Applications are due on January 17th, 2020.
Applicants must have an academic appointment at Harvard Medical School or Harvard T.H. Chan School of Public Health at the level of Assistant Professor or higher. Proposals will be accepted from from outside investigators will be considered, as long as a DF/HCC or HMS/TCCSPH-based investigator is involved. While the proposed research can be basic or clinical, bench-to-bedside and bedside-to-bench strategies need to be addressed, since the purpose of the SPORE is to promote translational research. All basic research supported by the SPORE must have a plan for translation into application or studies in humans within the 5 years of the grant proposal. To facilitate translation, such projects should be co-led by basic and clinically oriented scientists.
|REQUEST FOR APPLICATIONS:||Immunotherapy Toxicity SPORE for Translational Research Projects|
|AWARD AMOUNT:||3 to 4 awards of $100,000-150,000 in yearly direct costs for 2-5 years|
|KEY DATES:|| |
Application Deadline: January 17, 2020
Final Project Selection: February 29, 2020
Final Application: September 2020
We are seeking a 2-4-page pre-application with project specific aims, background and significance, research plan (preliminary data, experimental methods), plans for translation and anticipated timeline (see below). Pre-applications will be judged on their scientific merit, translational potential, relevance to cancer patients treated with Immunotherapy (including cell-based therapy such as CAR T cells and immune checkpoint inhibitors), qualifications of the research team, and the potential fit within the overall activities of the DF/HCC Cancer Immunology Program and the SPORE. Some pre-applications will be selected for presentation at project review sessions to be held in early 2020.
Final project selections will be made by the Immunotherapy Toxicity SPORE Leadership Committee in conjunction with its Internal Advisory Board by February 29, 2020. Ultimately, 3-4 projects will be included in the final SPORE application that is due in September 2020. If the SPORE grant is funded, the project awards will be granted at a level of approximately $100,000-150,000 in yearly direct costs for 2-5 years. The awardees will be asked to apply for membership in the DF/HCC Cancer Immunology Program and will be expected to participate in SPORE activities (e.g. meetings, retreats, and research presentations). Women and underrepresented in medicine (URiM) investigators are encouraged to apply. Application packages are due Friday, January 17, 2020 in PDF format.
Please contact Carolyn Hoban, ScD with any questions. Please send completed proposal electronically to CHOBAN@mgh.harvard.edu